Ionis Pharmaceuticals SEC Filings

Richard S. Geary, Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals (IONS), reported the sale of 10,000 shares of common stock on 09/02/2025. The shares were sold at a weighted average price of $50.3671 per share (individual trades ranged from $50.01 to $50.92). After the reported disposition, Mr. Geary beneficially owns 79,657 shares. The filing states the sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025, and the filer offers to provide trade-level detail on request.

Shannon L. Devers, EVP & Chief Human Resources Officer of Ionis Pharmaceuticals (IONS), reported multiple transactions on September 3, 2025. The filing shows sales of 3,162 shares at a weighted average price of $61.0192 reported as executed under a Rule 10b5-1 trading plan adopted September 3, 2024. The reporting person also acquired 2,234 shares and acquired by option exercise 928 shares at stated prices.

The Form 4 lists two non-qualified stock option exercises that vest from 01/03/2023 and 01/03/2024 with expiration dates in 2032 and 2033 and shows 15,009 shares held after the sale.

Joseph H. Wender, a director of Ionis Pharmaceuticals, Inc. (IONS), reported sales of company common stock under a Rule 10b5-1 trading plan. On 09/02/2025 he sold 11,200 shares at a weighted average price of $55.0386 and 5,600 shares at a weighted average price of $57.5311, and on 09/03/2025 he sold 11,200 shares at a weighted average price of $60.1383. Following those transactions, the filing reports beneficial ownership levels of 125,635, 120,035 and 108,835 shares respectively, each listed as held indirectly by trust. The Form 4 states the trades were made pursuant to a 10b5-1 plan adopted December 16, 2024, and provides price ranges for the multiple executions behind each weighted average.

Joseph T. Baroldi, Executive Vice President and Chief Business Officer of Ionis Pharmaceuticals (IONS), reported multiple transactions dated 09/03/2025. The filing shows purchases/issuances of non-qualified stock options with a $31.80 exercise price totaling 32,800 options (three grants/exercises of 2,800, 15,000 and 15,000) that underlie common stock. On the same date the reporting person sold 32,800 common shares in multiple transactions at weighted average prices of $62.0101 and $59.0864 as noted. The Form 4 states the sales were made pursuant to a Rule 10b5-1 trading plan adopted May 2, 2025. Following the reported transactions, the filing lists various beneficial ownership totals and discloses 3,071 shares indirectly owned by spouse.

Patrick O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals (IONS), filed a Form 4 reporting multiple transactions on September 2–3, 2025. The filing shows exercises of non-qualified stock options and contemporaneous sales executed under a Rule 10b5-1 trading plan adopted May 2, 2025. Reported option exercises include 13,050 shares at a $32.60 strike, 14,000 at $37.58, and 49,800 at $53.77. Reported sales under the 10b5-1 plan include 13,050 shares at a weighted average $54.5148, 65,475 shares at a weighted average $60.89, and 11,375 shares at a weighted average $61.42. The Form discloses the number of shares beneficially owned following each transaction line as reported in the filing.

C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), reported multiple transactions in early September 2025. He sold shares under a Rule 10b5-1 trading plan adopted May 13, 2025, and reported sales on 09/02/2025 and 09/03/2025 at weighted-average prices of $49.14 and ranges around $60.25–$61.995 and $61.26–$61.995 as disclosed. On 09/03/2025 he also acquired 46,800 shares by exercise/conversion of non-qualified stock options with a $53.77 exercise price. Following the reported activity, his beneficial ownership is reported as 88,679 shares.

Joseph Loscalzo, a director of Ionis Pharmaceuticals (IONS), reported paired transactions on 09/03/2025. He exercised 16,000 non-qualified stock options with an exercise price of $24.42 (options originally granted 07/01/2017, expiring 06/30/2026) and thereby acquired 16,000 shares. The same day he sold 16,000 shares under a Rule 10b5-1 trading plan adopted August 13, 2024, at a weighted-average price of $60.1482 (sales ranged from $60.00 to $60.57). The Form 4 shows 36,330 shares beneficially owned following these transactions.

Eugene Schneider, EVP and Chief Clinical Development Officer of Ionis Pharmaceuticals (IONS), reported option exercise and subsequent share sales executed on 09/03/2025. Schneider exercised a non-qualified stock option to acquire 19,658 shares at an exercise price of $53.77, which increased his beneficial ownership to 71,165 shares. He then sold 12,455 shares at a weighted average price of $60.4608, reducing ownership to 58,710, and sold an additional 7,203 shares at a weighted average price of $61.4163, bringing beneficial ownership to 51,507 shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 2, 2025. The Form 4 includes weighted-average price ranges for the sales and an undertaking to provide transaction price breakdowns on request.

Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals (IONS), reported a non-derivative purchase of 331 shares of Ionis common stock on 08/29/2025 at a price of $27.71 per share under the company's Amended and Restated 2000 Employee Stock Purchase Plan. After the purchase O'Neil beneficially owned 57,130 shares. The filing notes these ESPP-acquired shares may not be sold until 03/02/2026. The Form 4 is a single-person filing and reflects a routine employee-plan purchase rather than a sale or option exercise.